Graham Jackson

9PUBLICATIONS
70CO-AUTHORS
Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyNanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Feb 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.

Martin F Kaiser, Pieter Sonneveld, David A Cairns

|Aug 12, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm.

Charlotte Pawlyn, Fredrik H Schjesvold, David A Cairns

|Jan 09, 2024
Genomic Classification and Individualized Prognosis in Multiple Myeloma.

Francesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu

|Jun 14, 2023
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.

Martin F Kaiser, Andrew Hall, Katrina Walker

|Mar 16, 2023
Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic.

Jonathan Carmichael, Frances Seymour, Graham McIlroy

|Dec 21, 2022
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial.

Matthew W Jenner, Charlotte Pawlyn, Faith E Davies

Pageof 2

Frequent Collaborators

6 joint publications

Martin Kaiser

5 joint publications

David A Cairns

5 joint publications

Gordon Cook

4 joint publications

Charlotte Pawlyn